Market Place
Sourcing Support
Sanbexin® Significantly Reduces Stroke Disability at TASTE-2
25 Oct 2024 //
PR NEWSWIRE
Mitsubishi Tanabe Presents Radicava® Ph 3 Results At NEALS 2024
21 Oct 2024 //
PR NEWSWIRE
Mitsubishi America to Showcase ALS Research at 2024 AANEM Meeting
15 Oct 2024 //
PR NEWSWIRE
Mitsubishi Tanabe Presents RADICAVA ORS Data At AMCP Nexus
10 Oct 2024 //
PR NEWSWIRE
Mitsubishi Tanabe To Present Radicava ORS® Data At NASP Meeting
06 Oct 2024 //
PR NEWSWIRE
Mitsubishi Tanabe To Showcase RADICAVA ORS® Presentations At Meeting
17 Sep 2024 //
PR NEWSWIRE
Mitsubishi Tanabe To Present At American Neurological Association Meeting
12 Sep 2024 //
PR NEWSWIRE
Mitsubishi To Present RADICAVA ORS Real-World Data At ALS Conference
09 Jul 2024 //
PR NEWSWIRE
Mitsubishi Tanabe Presents RADICAVA® Results For ALS At ENCALS 2024
17 Jun 2024 //
PR NEWSWIRE
Mitsubishi Tanabe: Highlighting ALS Research At ENCALS 2024
05 Jun 2024 //
PR NEWSWIRE
Simcere Phar-maceuticals Presented Six Studies on Sanbexin® at ESOC 2024
21 May 2024 //
PR NEWSWIRE
Dr Reddys Labs` Generic Edaravone Receives Approval in the U.S
06 May 2024 //
FDA
Long Grove Pharma`s Generic Edaravone Receives Approval In US
06 May 2024 //
FDA
Hikma`s Generic Edaravone Receives Approval in the U.S.
06 May 2024 //
FDA
Gland Pharma`s Generic Edaravone Receives Approval in the U.S
06 May 2024 //
FDA
Mitsubishi Tanabe To Present RADICAVA ORS® Real-World Data
03 May 2024 //
PR NEWSWIRE
Mitsubishi Tanabe: RADICAVA® ALS Healthcare Resource Use At AMCP
15 Apr 2024 //
PR NEWSWIRE
MTP America Receives U.S. FDA Orphan Drug Exclusivity for RADICAVA
08 Apr 2024 //
PR NEWSWIRE
Mitsubishi Tanabe America gets US FDA orphan drug exclusivity Radicava ORS
08 Apr 2024 //
PHARMABIZ
Ferrer reports top-line results from Phase III ADORE study in ALS
10 Jan 2024 //
PRESS RELEASE
Mitsubishi Announces Analysis Examining Effect of Intervention with RADICAVA
17 Aug 2023 //
PR NEWSWIRE
FDA Confirms Paragraph IV Patent Litigation for Edaravone Oral Suspension
15 Jun 2023 //
FDA
Mitsubishi Tanabe Pharma Celebrates One-Year Anniversary of RADICAVA ORS
15 Jun 2023 //
PR NEWSWIRE
Mitsubishi Tanabe to Present Latest Findings Across ALS & PD at 2023
20 Apr 2023 //
PR NEWSWIRE
Mitsubishi TAnnounces Enrollment Completion for Phase 3b Study of RADICAVA ORS
23 Mar 2023 //
PR NEWSWIRE
Tanabe Pharma Announces 10,000 People with ALS Treated with RADICAVA ORS
16 Mar 2023 //
PR NEWSWIRE
RADICAVA ORS Added to U.S. Department of Veterans Affairs National Formulary
10 Mar 2023 //
PR NEWSWIRE
Mitsubishi Announces 4,000 ALS Patients in Have Been Treated with RADICAVA ORS
26 Jan 2023 //
PR NEWSWIRE
Mitsubishi Tanabe Pharma America Presents Data on RADICAVA ORS
21 Sep 2022 //
PRNEWSWIRE
ICER panel says two ALS drug candidates have `low` long-term value
20 Aug 2022 //
ENDPTS
Mitsubishi Tanabe Announces Real-World Data Analysis of Survival with RADICAVA
15 Aug 2022 //
PRNEWSWIRE
Mitsubishi Tanabe Pharma America Shows Long-Term Results of RADICAVA PMS Study
29 Jun 2022 //
PRNEWSWIRE
RADICAVA ORS® (edaravone) Now Available in the U.S. for the Treatment of ALS
15 Jun 2022 //
PRNEWSWIRE
Mitsubishi Tanabe Presents 48-Week Result from PIII Safety Study of RADICAVA ORS
01 Jun 2022 //
PRNEWSWIRE
FDA Approves RADICAVA ORS Oral Suspension for ALS by Mitsubishi Tanabe
26 May 2022 //
PRNEWSWIRE
Mitsubishi Tanabe Pharma America Presents Real-World Data on RADICAVA at AAN
04 Apr 2022 //
PRNEWSWIRE
MTPA Announces FDA Acceptance of NDA for Oral Edaravone Formulation
12 Jan 2022 //
PRNEWSWIRE
Mitsubishi Tanabe Announces Results from Phase 3 Safety Study of Oral Edaravone
09 Dec 2021 //
PRNEWSWIRE
Post-Hoc Analysis of Phase 3 Study in ALS Patients Announced
18 Mar 2021 //
PRNEWSWIRE
Mitsubishi Tanabe Pharma America Presents Real-World Experience Outcomes
11 Dec 2020 //
PRNEWSWIRE
Mitsubishi Tanabe America Announces the Global Pha3 of Oral Edaravone
09 Nov 2020 //
PRNEWSWIRE
Mitsubishi Tanabe America Announces Presentations Northeast Amyotrophic Lateral
30 Sep 2020 //
PRNEWSWIRE
Mitsubishi Canada Announces ALS Treatment now Eligible for VAC and ISC Coverage
21 Sep 2020 //
BIOSPACE
Mitsubishi Tanabe America Announces Enrollment Has Resumed For The Global Ph3
24 Aug 2020 //
PRNEWSWIRE
Mitsubishi Tanabe Pharma Canada Announces That Treatment For (ALS)
19 Aug 2020 //
BIOSPACE
Mitsubishi Tanabe Pharma America Honors Third Anniversary Of RADICAVA®
05 Aug 2020 //
PRNEWSWIRE
Mitsubishi Tanabe Pharma Canada Announces that Manitoba has Added
30 Jun 2020 //
BIOSPACE
Mitsubishi Tanabe Pharma America Announces Launch Of The JourneyMate Program
20 May 2020 //
PRNEWSWIRE
Mitsubishi Tanabe Pharma Canada Announces That Company`s Treatment for (ALS)
29 Apr 2020 //
BUSINESSINSIDER
Mitsubishi Tanabe Canada Concludes Letter of Intent with Pan-Canadian RADICAVA
22 Apr 2020 //
NEWSWIRE
New Post-hoc Analysis of Phase 3 Study Examines Edaravone in ALS Patients
24 Mar 2020 //
PR NEWSWIRE
First patient enrolled in Oxford BioDynamics’ ALS biomarker study
25 Oct 2019 //
PHARMATIMES
Mitsubishi Tanabe, Daiichi Sankyo tie alliance for ALS treatment agent
18 Sep 2019 //
BIOSPAECTRUMASIA
More Than 4,000 U.S. Patients With ALS Treated With RADICAVA® (edaravone)
08 Aug 2019 //
PR NEWSWIRE
Mitsubishi Tanabe pulls Radicava app
31 May 2019 //
FIERCE PHARMA
Samsung BioLogics` crisis; Merck`s Gardasil supply; China’s vaccine solution
16 Nov 2018 //
FIERCE PHARMA
Mitsubishi Tanabe spotlights overlooked teen ALS caregivers with artistic effort
14 Nov 2018 //
FIERCE PHARMA
Orion takes repurposed heart drug into phase 3 for ALS
06 Jul 2018 //
FIERCE BIOTECH
Mitsubishi Tanabe America to Present Data on RADICAVA®at (ENCALS) Meeting
21 Jun 2018 //
PR NEWSWIRE
Health Canada Accepts Mitsubishi Tanabe Corporation`s NDS Filing for Edaravone
09 Apr 2018 //
NEWSWIRE
